Compositions and methods for treating neoplasia, inflammatory disease and other disorders
US-8981083-B2 · Mar 17, 2015 · US
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
US9320741B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9320741-B2 |
| Application number | US-201414502840-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 30, 2014 |
| Priority date | May 14, 2010 |
| Publication date | Apr 26, 2016 |
| Grant date | Apr 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a condition in a subject in need thereof, the method comprising administering to the subject an effective amount of any one of compounds represented by the following structural formulas or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the group consisting of prostate cancer, renal cell carcinoma, hepatoma, lung cancer, breast cancer, colon cancer, neuroblastoma, glial blastoma multiforme, squamous cell carcinoma involving a NUT rearrangement, NUT midline carcinoma and non-small cell lung cancer. 2. The method of claim 1 , wherein the compound is represented by the structural formula or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the compound is represented by the structural formula or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , wherein the compound is represented by the structural formula or a pharmaceutically acceptable salt thereof. 5. The method of claim 1 , wherein the lung cancer is small cell lung cancer. 6. The method of claim 1 , wherein the lung cancer is non-small cell lung cancer. 7. The method of claim 1 , wherein the condition is NUT midline carcinoma. 8. The method of claim 1 , wherein the condition is prostate cancer. 9. The method of claim 1 , wherein the condition is renal cell carcinoma. 10. The method of claim 1 , wherein the condition is hepatoma.
Assignees
Inventors
Classifications
- C07D495/14Primary
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title
Antineoplastic agents · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9320741B2 cover?
- The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).
- Who is the assignee on this patent?
- Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D495/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).